CRISPR Therapeutics AG
METHODS AND COMPOSITIONS OF CYTOTOXIC T CELL DEPLETION

Abstract:

The present application relates to compositions and methods for controlled cytotoxic T cell depletion, such as for the treatment of various diseases and conditions associated with cytotoxic T cells. The application provides engineered T cells comprising inter alia nucleic acids encoding an anti-cytotoxic T lymphocyte (CTL) protein capable of conferring to the engineered T cell cytotoxicity towards a CTL. The anti-CTL protein may comprise an extracellular BETA2-microglobulin domain.